Follow CGSP on Social Media

Listen to the CGSP Podcast

JAMA’s Findings on Sinopharm’s Efficacy Will Allow Public Health Officials in the Global South to Sleep Better at Night

The prestigious Journal of the American Medical Association published results on Wednesday of new phase 3 clinical trials of Sinopharm’s COVID-19 vaccine and confirmed that the jab’s efficacy rate is between 72-78%.

More importantly, the trials also confirmed that Sinopharm’s vaccine prevents hospitalization and death in almost all instances, which is critical for developing countries with weak public health systems. So, even if people get infected, they can recover at home without overburdening local hospitals.

Lead the Conversation on China

Subscribe Today to Get Full Access to The China-Global South Project

Check Out Everything You'll Get With Your Subscription

The China-Global South Daily Brief delivered to your inbox at 6AM Washington time

Full access to exclusive news and analysis from editors based in the Global South

Transcripts of CGSP’s twice-weekly podcasts

Students and teachers with a valid .edu email address are eligible for a 50% discount off monthly or yearly subscriptions. Email us to receive a discount code.

What is The China-Global South Project?


The China-Global South Project is passionately independent, non-partisan and does not advocate for any country, company or culture.


A carefully curated selection of the day’s most important China-Global South stories. Updated 24 hours a day by human editors. No bots, no algorithms.


Diverse, often unconventional insights from scholars, analysts, journalists and a variety of stakeholders in the China-Global South discourse.


A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.